Summit Therapeutics’ stock price $SMMT tumbled nearly 20% after the closing bell Thursday afternoon, following an apparent statistical miss in part of a Phase 3

Amgen has taken steps to update its Tavneos label amid an ongoing battle with the FDA. The company filed a supplement on Wednesday that would

Moderna saw its Q1 sales nearly triple to $389m, almost a threefold rise on the same period of 2025, with international markets driving the increase.

The FDA’s cancer drugs committee backs AstraZeneca’s Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.

Johnson & Johnson is scrapping two CAR-T cell programs for B cell lymphoma amid a wave of approvals in recent years for cell therapies and